Evidence map›Paper›PMID 38392579›Full record

ArticleJournal of personalized medicine2024

Towards Personalized Treatment in Haemophilia: The Role of Genetic Factors in Iron and Heme Control to Identify Patients at Risk for Haemophilic Arthropathy.

Lize F D van Vulpen, Simon C Mastbergen, Wouter Foppen, Kathelijn Fischer, Floris P J G Lafeber, Roger E G Schutgens

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lize F D van VulpenCentre for Benign Hematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands.ORCID 0000-0003-3242-5524
Simon C MastbergenDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, University Utrecht, 3508 GA Utrecht, The Netherlands.
Wouter FoppenDepartment of Radiology and Nuclear Medicine, Division of Imaging & Oncology, University Medical Center Utrecht, University Utrecht, 3508 GA Utrecht, The Netherlands.ORCID 0000-0003-4970-8555
Kathelijn FischerCentre for Benign Hematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands.
Floris P J G LafeberDepartment of Rheumatology & Clinical Immunology, University Medical Center Utrecht, University Utrecht, 3508 GA Utrecht, The Netherlands.
Roger E G SchutgensCentre for Benign Hematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands.
Utrecht University · NL

Funding

CSL (Germany) N/a, unrestricted grant
6 · The paper itself

Abstract

The treatment landscape for haemophilia is changing rapidly, creating opportunities for personalized treatment. As major morbidity is still caused by haemophilic arthropathy, understanding the factors affecting joint damage and joint damage progression might lead to more individualized treatment regimens. We investigated the association of

Indexed as

arthropathyhaemophiliaHFEHMOX1personalized medicine

Identifiers

PMID38392579
PMCPMC10890487
OpenAlexW4391323162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.